Onset Apr 1, 2014 · The most frequent specific grade ≥ 3 toxicity was HFS (n = 206), followed by diarrhea (n = 97), and neutropenia (n = 19)
Methods Capecitabine, dFCR, and FBAL pharmacokinetics were well described by two‐compartment models, and dFUR and 5‐FU were subject to flip‐flop pharmacokinetics
In recent years, the incidence of this side effect has increased and it is expected to further rise due to the population aging and the disproportionate incidence of breast and gastrointestinal cancers in older individuals
As with other cytotoxic drugs, the interpatient variability of the pharmacokinetic parameters of capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine and fluorouracil, is high (27 to 89%) and is likely to be primarily due to variability in the activity of the enzymes involved in capecitabine metabolism
a frequent late-onset toxicity which occurred in seven patients throughout the study period Capecitabine, a prodrug of the antimetabolite 5-fluorouracil (5-FU), has been registered for treatment of colon cancer in the adjuvant setting as well as for treatment of advanced colon, breast and gastric cancer
Capecitabine is activated to 5-FU by CES, CDA and TYMP, Capecitabine is an oral chemotherapy prodrug of 5-fluorouracil (5-FU) with unpredictable toxicity, especially in older adults
Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer treatment
Here, we examined the effects of CES1 variants on pharmacokinetics and toxicity of capecitabine
physicians routinely prescribe 1,000 mg/m 2
Adherence was assessed using a pill count, pharmacy data and dosing information from the patients' medical file
2° Doses of 666 or 1255 mg/m 2 given twice daily were administered either after an overnight fast or within 30 minutes of finishing a standard breakfast on days 1 and 8
Once a dosage has been reduced for toxicity, it should not be increased at a later time
31; P = 9
Methods Here, we examined the effects of CES1 variants on pharmacokinetics and toxicity of capecitabine
The majority of patients had an advanced stage disease
AIM Capecitabine, designed as a pro-drug to the cytotoxic agent 5-fluorouracil, is widely used in the management of colorectal cancer
Genetic factors may affect the efficacy and toxicity of capecitabine related to the activity of the enzymes involved in its metabolism
25 h
Capecitabine is a prodrug that undergoes metabolism in three steps to form an active 5-fluorouracil (5-FU)
Citation 46
Effect of Renal Impairment on the Pharmacokinetics of Capecitabine, 5’-DFUR, and FBAL
The relationship between diurnal changes in capecitabine and 5-FU plasma levels is important in terms of evaluating the efficacy and toxicity of the treatment
Following oral administration it is enzymatically converted to 5-FU, the active compound
1 Severe, life-threatening, and even fatal toxicity has been associated with deficient dihydropyrimidine dehydrogenase (DPYD) activity in patients receiving fluoropyrimidine-based chemotherapy at standard doses
Capecitabine and other modifiers of 5-FU pharmacokinetics described by Dr
Purpose To address tolerability and a possible pharmacologic interaction of capecitabine with sorafenib
0 mmol/kg and the AUCs of 5'-DFUR were approximately 40 to 60 microg*hr/ml
For breast cancer it is often used together with docetaxel
Excessive folate intake may be avoided before and during capecitabine-based chemotherapy
We reviewed the records of patients treated with capecitabine in an oncology department of a University Clinic in Nijmegen, The Netherlands
However, a direct assessment of efficacy based on when emergency treatmen
The population pharmacokinetic analysis failed to describe FBAL A 59-year-old Indian woman was diagnosed with metastatic colon cancer and started on a neoadjuvant treatment regimen of capecitabine (3 500-mg tablets orally twice a day), oxaliplatin, and bevacizumab (a treatment time line is presented in Fig 1)
In recent years, the incidence of this side effect has increased and it is expected to further rise due to the population aging and the disproportionate incidence of
Capecitabine is activated to 5-FU by CES, CDA and TYMP, of which SNPs in CDA and CES2 were found to be associated with efficacy and toxicity
Purpose: The present study was performed to examine relationships between systemic exposure of capecitabine metabolites (5-FU, 5'-DFCR and 5'-DFUR) and toxicity or
Abstract Purpose: Capecitabine is a prodrug that undergoes metabolism in three steps to form an active 5-fluorouracil (5-FU)
Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies
The broader clinical use of bispecific T cell engagers for inducing anti-tumour toxicity is hindered by their on-target off-tumour toxicity and the associated
From the pharmacokinetic point of view and in agreement with numerous clinical study data, co-administration of BVZ with CCB appears to be safe and efficient
Capecitabine is activated to 5-FU by CES, CDA and
In Caucasian patients, higher plasma concentrations of FBAL were measured than in Japanese patients
Here we evaluated the association of genetic variability in all enzymes of the Cp-activation pathway to 5-fluorouracil with Cp-related early-onset toxicity in In this work, we present a new and multilayer organs-on-a-chip device that allows for the assessment of drug metabolism, and its resultant drug efficacy and cytotoxicity in different organ-specific cells simultaneously
AUC last for capecitabine was 28 ± 10 μg
Background Capecitabine is an oral chemotherapy prodrug of 5-fluorouracil (5-FU) with unpredictable toxicity, especially in older adults
Methods A population pharmacokinetic model for capecitabine and its three metabolites was built
tested in cohorts of cancer patients and possibly useful for prediction of capecitabine efficacy or toxicity
Genetic factors may affect the efficacy and toxicity of capecitabine related to the activity of the enzymes involved in its metabolism
platinum salts, irinotecan, methotrexate, intravenous bisphosphonates)
Rider, in xPharm: The Comprehensive Pharmacology Reference, 2007 Introduction
Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) that is rapidly and extensively absorbed in the intestine before conversion to 5-FU
Sarcopenia is a significant predictor of toxicity and TTP in metastatic breast cancer patients treated with capecitabine
Partial and total gastrectomy were associated with a significantly faster capecitabine absorption resulting in higher capecitabine and metabolite peak concentrations